

ACTIVE CLINICAL STUDY

Presently Enrolling Medically Inoperable NSCLC Patients

STUDY A Prospective Evaluation of Outcomes of Radiosurgical Treatment for Early Stage Non-Small Cell Lung Cancer (NSCLC)

PRINCIPLE INVESTIGATOR James Luketich, M.D., Chief of Thoracic and Foregut Surgery
University of Pittsburgh Medical Center, Pittsburgh, PA

SPONSOR Accuray Incorporated

PRIMARY AIMS

1. To assess clinical response rate, local control, progression-free survival and overall survival following CyberKnife® Stereotactic Radiosurgery (SRS) for patients with early stage NSCLC with 5 year follow-up

SECONDARY AIMS

1. To characterize and compare quality of life before and after SRS treatment
2. To assess quality of life in this population following treatment
3. To assess procedure-related outcomes after SRS of lung tumors— in particular, morbidity and mortality, and requirements for chest tube drainage

PATIENT POPULATION Medically inoperable patients with early stage NSCLC

STAGE I:

T1 N0 M0

T2 N0 M0 (Size ≤ 5 cm)

STAGE II:

T3 N0 M0 (Chest wall invasion only, Size ≤ 5 cm)

METHODS Primary treatment of solitary lung tumors by CyberKnife radiosurgery

Peripheral Lesions: 20 Gy x 3 fractions

Central Lesions: 12 Gy x 4 fractions

PARTICIPATING CENTERS

University of Pittsburgh Medical Center, PA (Principal Investigator Site)
Georgetown University Hospital, Washington, DC
Stanford University, CA
St. Joseph's/Barrow Neurological Institute, AZ
Fresno Community Regional Medical Center, CA
Baylor University Medical Center, TX
St. Catherine Hospital, IN
St. Anthony Hospital, OK
North Florida Regional Medical Center, FL
Sinai Hospital of Baltimore, MD
St. Luke's/Aurora Medical Center, WI
Naples Community Hospital, FL

For more information regarding potential patient enrollment, please contact Omar Dawood, MD, MPH, Vice President, Clinical Development at odawood@accuray.com or 408.789.4457.

